Meeting
2019 ASCO Annual Meeting
Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer.
Authors
Sebastian Mondaca
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Sebastian Mondaca , Henry S Walch , Subhiksha Nandakumar , Walid K. Chatila , Jaclyn Frances Hechtman , Andrea Cercek , Luis A. Diaz Jr., Francisco Sanchez-Vega , Nancy E. Kemeny , Neil Howard Segal , Zsofia Kinga Stadler , Anna M. Varghese , Efsevia Vakiani , Marc Ladanyi , Michael F. Berger , David B. Solit , Jinru Shia , Leonard B. Saltz , Nikolaus D Schultz , Rona Yaeger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3585)
DOI
10.1200/JCO.2019.37.15_suppl.3585
Abstract #
3585
Poster Bd #
77
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Mutational landscape of pancreatic adenocarcinoma identified by prospective clinical sequencing in a nationwide cancer network.
First Author: Katherine E Poruk
Poster
2022 ASCO Annual Meeting
Evaluation of stage IV pancreatic adenocarcinomas based on mutational profiling of tumors.
First Author: Katherine E Poruk
Poster
2021 Gastrointestinal Cancers Symposium
ARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC).
First Author: Michael Cecchini
Poster
2019 ASCO Annual Meeting
BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.
First Author: Madiha Naseem